Product Images Dexmethylphenidate Hydrochloride

This is a description of a medication called Dexmethylphenidate Hydrochloride Extended-Release capsules, with a NDC code of 43602-328-30. The medication guide should be given separately to the patient. Each capsule contains 10 mg of hydrochloride and should be stored at temperatures between 20°C to 25°C, with acceptable excursions between 15°C to 30°C. It must be stored in a tight container with child-resistant closure and out of reach of children. The manufacturer is Ascent Pharmaceuticals Inc. located at Central Tslip, NY 11722.*

This is a description of a medication labeled as "Dexmethylphenidate Hydrochloride Extended-Release Capsules". These capsules are provided separately for each patient by the pharmacist. Each capsule contains 10 mg of Dexmethylphenidate hydrochloride and should be taken as per the package insert. They should be stored between 20°C to 25°C (68°F to 77°F) with excursion permitted between 15°C to 30°C (59°F to 86°F). The medication should be dispensed in a tight container with a child-resistant closure. The manufacturer of this medication is Ascent Pharmaceuticals, Tnc. It is for Rx use only and should be kept out of reach of children.*

This is a description of a medication with the NDC code 43602-329-30. The medication is Dexmethylphenidate Hydrochloride Extended-Release Capsules, with each capsule containing 15 mg of Dexmethylphenidate hydrochloride. The medication guide should be dispensed separately for each patient. The dosage information is provided in the package insert. The medication should be stored between 20°C to 25°C (68°F to 77°F), with excursions allowed between 15°C to 30°C (59°F to 86°F). It should be kept in a tight container with a child-resistant closure and out of reach of children. The drug is manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY.*

This is a prescription drug with NDC 43602-329-05 used to treat attention deficit hyperactivity disorder (ADHD). It comes in the form of extended-release capsules containing 15mg of Dexmethylphenidate hydrochloride. The medication guide should be provided separately to each patient. It is recommended to store the drug in a tight container with a child-resistant closure at a temperature range of 20°C to 25°C (68°F to 77°F), with excursions allowed within 15°C to 30°C (59°F to 86°F). The dosage information can be found in the package insert. Manufactured by Ascent Pharmaceuticals in Central Islip, NY 11722. Children should be kept away from this and all drugs.*

This is a medication called Dexmethylphenidate Hydrochloride Extended-Release Capsules. Each capsule contains 20mg of the active ingredient. It is important to dispense the medication guide provided separately for each patient. The medication should be stored at a controlled room temperature and in a tight container with a child-resistant closure. This medication is available in a package of 30 capsules and should only be taken as directed by the package insert. The manufacturer of this medication is Ascent Pharmaceuticals, Inc. located in New York.*

The text describes a medication called Dexmethylphenidate Hydrochloride Extended-Release Capsules with NDC 43602-330-05. Each capsule contains 20 mg of Dexmethylphenidate hydrochloride with dosages specified in the package insert. It comes in a container that is child-resistant with 500 capsules for prescription only. The medication guide should be given to each patient. The medication should be stored between 20°C to 25°C (68°F to 77°F), with excursions allowed between 15°C to 30°C (59°F to 86°F). The medication is manufactured by Ascent Pharmaceuticals, Tnc in Central Tslip, NY 11722.*

NDC 43602-331-30 is a medication used for the treatment of attention deficit hyperactivity disorder (ADHD). The medication comes in the form of extended-release capsules and contains 25mg of dexmethylphenidate hydrochloride. The medication must be stored at a temperature between 20°C to 25°C (68°F to 77°F) and a tight container with a child-resistant closure must be used to dispense the medication. The medication guide must be dispensed separately for each patient by the pharmacist. This medication is only available by prescription and should be kept out of the reach of children. It is manufactured by Ascent Pharmaceuticals, Inc.*

This is a medication called Dexmethylphenidate which is in an extended-release capsule form. Each capsule contains 25mg of hydrochloride. The pharmacist is instructed to provide a medication guide to the patient separately. Dosage information is available in the package insert. It should be stored in a tight container with child-resistant closure at 20°C to 25°C (68°F to 77°F); excursions permitted 15°C to 30°C (59°F to 86°F). It is manufactured by Ascent Pharmaceuticals, Tnc in Central Tslip, NY 11722.*

Dexmethylphenidate Hydrochloride is an extended-release drug provided in 30 capsules each containing 30 mg of the compound. The dosage instructions are specified in the package insert. Pharmacists should dispense the medication guide separately to every patient. The drug should be stored in a tight container with a child-resistant closure between 20°C to 25°C; however, excursions between 15°C to 30°C are allowable. Ascent Pharmaceuticals, Inc., centrally located in Central Islip, NY 11722, manufacturers the drug. Remember to keep the drug out of children's reach.*

This is a medication called GOZEE or ZOGEY in capsule form. Each capsule contains 30 mg of Dexmethylphenidate hydrochloride, an extended-release medication used to treat attention deficit hyperactivity disorder (ADHD). The medication guide should be provided separately to each patient. The capsules should be stored at a temperature of 20°C to 25°C (68°F to 77°F), with permitted excursions from 15°C to 30°C (59°F to 86°F). The medication should be dispensed in a tight container with child-resistant closure, as per the USP. Ascent Pharmaceuticals, Inc. in Central Islip, NY is the manufacturer.*

The text describes a medication named Dexmethylphenidate Hydrochloride Extended-Release Capsules, with NDC code 43602-333-30, containing 30 capsules of 35 mg. The medication guide must be provided separately by the pharmacist to each patient. The recommended dosage is specified in the package insert. Storage instructions are also provided, and the medication must be stored in a tight container with a child-resistant closure at 20°C to 25°C (68°F to 77°F), with excursions permitted 15°C to 30°C (39°Fto 86°F). The manufacturer of the medication is Ascent Pharmaceuticals, Inc, based in Central Islip, NY 11722.*

This is a prescription drug with the NDC code 43602-333-05. It comes in the form of extended-release capsules with 35mg of hydrochloride. The dosage instructions are available in a package insert. It should be stored at a controlled room temperature of 20-25°C (68°F to 77°F) and dispensed in a tight container with child-resistant closure. The medication guide should be provided separately to each patient. It is manufactured by Ascent Pharmaceuticals, Inc. and should be stored out of the reach of children.*

This is a description of a medication called Dexmethylphenidate Hydrochloride Extended-Release Capsules. Each capsule contains 40mg of the active ingredient and is intended for Rx only. The medication guide should be dispensed to each patient by a pharmacist. The drug should be stored at 20°C to 25°C (68°F to 77°F) and should be kept out of reach of children. The manufacturer is Ascent Pharmaceuticals, Inc based in Central Islip, NY 11722.*

This is information about a medication that comes in extended-release capsules with 40mg of Dexmethylphenidate Hydrochloride. The dosage details are available in the package insert. The capsules should be stored between 20°C to 25°C (68°F to 77°F), with brief excursions permitted between 15°C to 30°C (56°F to 86°F) as per USP Controlled Room Temperature guidelines. The medication should be dispensed in a tight container as defined by USP, and the pharmacist should provide the medication guide separately to each patient. The medication is manufactured by Ascent Pharmaceuticals, Inc. and is only available on a prescription.*

This is a medication called Dexmethylphenidate Hydrochloride Extended-Release Capsules in a 30 capsule prescription. The pharmacist must dispense the medication guide to each patient separately. Each capsule contains 5mg of Dexmethylphenidate Hydrochloride and the dosage information can be found in the package insert. The medication should be stored between 20°C to 25°C (68°F to 77°F) with permitted excursions between 15°C to 30°C (59°F to 86°F) and should be kept out of the reach of children in a tight container with a child-resistant closure as defined in USP. The manufacturer is Ascent Pharmaceuticals, Inc. located in Central Islip, NY 11722. Rev date: 02/21.*

This is a description of Dexmethylphenidate hydrochloride extended-release capsules. It contains 500 capsules and each capsule has 5 mg of Dexmethylphenidate hydrochloride. Pharmacists are required to dispense medication guide provided separately to each patient. Dosage and storage instructions are provided in the package. It is manufactured by Ascent Pharmaceuticals, located in Central Tslip, NY, and must be stored in a tight container as defined in the USP, with a child-resistant closure at a temperature of 20 to 25 degrees Celsius.*

This appears to be a list of symptoms, including dyspepsia, decreased appetite, headache, and anxiety. It is possible that these symptoms are related to a medical condition, but without additional information or context it is difficult to determine the cause.*

This is a list of common side effects of a medication or medical condition. "Drymouth" and "dyspepsia" refer to dryness in the mouth and indigestion, respectively. "Headache" and "anxiety" refer to headaches and feelings of unease or nervousness. "Pharyngolaryngeal pain" refers to pain in the throat and/or larynx.*

The text describes a graph showing the plasma concentration of Dexmethylphenidate over time after administration of two different doses of the drug: 1x20mg extended-release capsules and 2x10mg immediate-release tablets. The graph depicts the mean concentration values obtained from a sample of 24 people for the extended-release capsules and 25 people for the immediate-release tablets. The x-axis shows time, and the y-axis shows the drug concentration in ng/mL.*

The given text provides a table that displays common adverse reactions in pediatric patients, aged 6 to 17 years, with ADHD after treatment with Dexmethylphenidate hydrochloride and Placebo extended-release capsules. The table represents the percentage of occurrences of various adverse reactions in groups of patients who have received medication and a placebo, respectively. The adverse effects listed in the table belong to multiple system organ classes, including Gastrointestinal Disorders, Metabolism and Nutrition Disorders, Nervous System Disorders, and Psychiatric Disorders. Some of the common adverse reactions observed in Dexmethylphenidate hydrochloride treated group include decreased appetite, dyspepsia, headache, and anxiety.*

This table presents the dose-related adverse reactions observed in pediatric patients with ADHD aged 6 to 17 years, who were administered Dexmethylphenidate Hydrochloride Extended-Release Capsules at 10mg/day, 20 mg/day, and 30mg/day doses, compared to placebo. Adverse reactions include gastrointestinal, metabolic and nutritional, psychiatric disorders and other adverse reactions, such as irritability, nasal congestion, and pruritus.*

This table presents dose-related adverse reactions in adult patients with Attention Deficit Hyperactivity Disorder (ADHD) attributable to Dexmethylphenidate Hydrochloride Extended-Release Capsules compared to a Placebo. The adverse reactions are classified into Gastrointestinal Disorders, Nervous System Disorders, Psychiatric Disorders, Respiratory, Thoracic, and Mediastinal Disorders. It reports the percentage of patients experiencing gastrointestinal disorders such as dyspepsia, nervous system disorders such as headache, psychiatric disorders such as anxiety, and respiratory, thoracic, and mediastinal disorders such as pharyngolaryngeal pain based on different doses of medication.*

This is a table showing the mean and standard deviation of the changes in vital signs and weight by randomized dose during double-blind treatment in adults taking Dexmethylphenidate Hydrochloride extended-release capsules and Placebo. The table includes the doses of 20mg, 30mg, and 40mg with corresponding sample sizes (N) of 57, 54, 54, and 53 respectively. Vital signs measured include pulse (bpm) and diastolic blood pressure (mmHg), while weight is measured in kilograms (kg).*

This is a table listing clinically important drug interactions with a medication called Dexmethylphenidate Hydrochloride Extended-Release Capsules. It highlights the potentially fatal consequences that can occur when CNS stimulants like Dexmethylphenidate are used with MAOIs, and recommends that they should not be used together or within 14 days of each other. The table also cautions that Dexmethylphenidate can reduce the effectiveness of certain antihypertensive drugs, and that it should not be used with halogenated anesthetics on surgery day. Additionally, if combined with risperidone medication, it may increase the risk of extrapyramidal symptoms.*

Table 6 summarizes the efficacy results obtained from a study of ADHD in pediatric patients aged 6-17 years. The primary efficacy measure was CADS-T Total Score, and the table shows the mean LS mean placebo-subtracted baseline change score (and its 95% confidence interval) for the treatment group (Dexmethylphenidate Hydrochloride Extended-Release Capsules) and the placebo group. The table also shows the number of patients in each group and their baseline scores (SD) and baseline change scores (SE).*

This table shows a summary of the results from a study on the efficacy of dexmethylphenidate hydrochloride extended-release capsules on adults with ADHD. The table presents the primary efficacy measure, ADHD-RS total score, for each treatment group, along with the mean baseline score, mean change from baseline, and placebo-subtracted difference. The study tested three different doses of the medication (20mg/day, 30mg/day, and 40mg/day) and a placebo group.*